<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01883154</url>
  </required_header>
  <id_info>
    <org_study_id>loe135673ctil</org_study_id>
    <nct_id>NCT01883154</nct_id>
  </id_info>
  <brief_title>The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome</brief_title>
  <official_title>The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genetic and environmental factors are believed to play a major role in intrauterine growth
      and intrauterine programming. We intend to study genetic factors such as Telomere
      homeostasis, senescence, genomic instability and the presence of Genomic copy number
      variations in placental tissue from pregnancies complicated with Intrauterine growth
      restriction(IUGR), Gestational and pre gestational Diabetes, placentas from IVF pregnancies
      and from normal pregnancies. We also intend to assess these factors in cord blood and
      maternal blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on the previous data from our group as well as other laboratories, we postulate that
      there is a correlation between impaired telomere homeostasis, senescence genomic instability
      and intra-uterine programming in placentas and in fetuses exposed to suboptimal intrauterine
      conditions such as hypoxia or hyperglycemia. Improved understanding of the mechanisms that
      produce the genomic changes in IUGR placentas and their influence on later risks of
      developing the metabolic syndrome should provide basis for future research that might lead
      into improved outcome of IUGR fetuses.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Rate of Copy Number Variations</measure>
    <time_frame>10 yeras</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Telomere length</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of copies of mitochondrial DNA</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Normal Pregnancies</condition>
  <arm_group>
    <arm_group_label>IUGR pregnancies</arm_group_label>
    <description>Pregnancies complicated with IUGR. Fetal growth beneath the 10th percentile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregnancies with Gestational Diabetes</arm_group_label>
    <description>Normal glucose levels before 20 weeks, and positive Oral glucose tolerance test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pre Gestational Diabetes</arm_group_label>
    <description>A diagnosis of Diabetes before pregnancy or elevated glucose levels before 20 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVF pregnancies</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      placental tissue ,fetal cord blood and maternal blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Samples from pregnancies complicated with IUGR, Gestational and pre gestational Diabetes,
        placentas from IVF pregnancies and from normal pregnancies. We intend to assess these
        factors in placental tissue, in cord blood and maternal blood.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of Intrauterine growth restriction

          -  A diagnosis of Gestational diabetes

          -  A diagnosis of pre gestational Diabetes

          -  IVF pregnancy

        Exclusion Criteria:

          -  chorioamnionitis

          -  meconium stained amniotic fluid

          -  A request of the patient for Cord blood retrieval for preservation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tal Biron Shental, MD</last_name>
    <phone>972-52-836-2331</phone>
    <email>Tal.Biron-Shental@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rivka Sukenik-Halevy, MD</last_name>
    <phone>972-52-6007249</phone>
    <email>riki.sukenik@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Meir medical center</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tal Biron Shental, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rivka Sukenik Halevy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tal Biron Shental, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2013</study_first_submitted>
  <study_first_submitted_qc>June 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2013</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

